News
-
-
PRESS RELEASE
Matador Secondary Private Equity AG: Matador generated a profit of CHF 6.3 million in the 2024 financial year and the net asset value increased by almost 12%
Matador Secondary Private Equity AG reported a profit of CHF 6.3 million and a 12% increase in net asset value for the 2024 financial year. The company shows confidence in future successful financial performance -
PRESS RELEASE
Orell Füssli Ltd: Orell Füssli significantly increases Revenue, EBIT and Net income in 2024
Orell Füssli significantly increases Revenue, EBIT and Net income in 2024. Revenue grows by 8.7%, EBIT increases by 24.5%, net income rises by 19.6% to CHF 17.5 million. Successful strategic projects concluded. Proposed dividend increase to CHF 4.40 per share -
-
PRESS RELEASE
Star Royalties Highlights Copperstone Project Economics and Stream Valuation
Star Royalties Ltd. highlights the reissuance of the Preliminary Economic Assessment on the Copperstone Gold Mine by Minera Alamos Inc., showcasing improved economics and stream valuation amid rising gold prices -
PRESS RELEASE
Relevant Gold Closes Second Tranche of Upsized $8.5 Million Non-Brokered Private Placement Led by Strategic Investors Kinross and Bollinger
Relevant Gold Corp. closes Tranche 2 of private placement, raising $7M+; Kinross and Bollinger lead investments, acquiring 19.9% each. Exploration and working capital to benefit -
PRESS RELEASE
Zomedica Reports Record Revenue of $7.9 Million for the Fourth Quarter and $27.3 Million for the Full Year 2024; 70% Gross Margin, and $71 Million in Liquidity to Support Growth
Zomedica Corp. reports strong financial results for Q4 and FY 2024, with record revenue and growth in Diagnostics segment. Company's focus on accelerated revenue growth in 2025 highlighted -
PRESS RELEASE
Fresh Vine Wine, Inc. To Change Corporate Name To Amaze Holdings, Inc. and Ticker Symbol to AMZE Following Strategic Acquisition
Fresh Vine Wine, Inc. changes name to Amaze Holdings, Inc. (NYSE: AMZE) after acquiring Amaze Software Inc. The rebrand signifies commitment to creator-driven commerce and growth -
-
PRESS RELEASE
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar Health announces voting results of Special Meeting of Stockholders and expect first results in Q2 2025 for crofelemer trials in rare diseases. FDA meeting anticipated for Phase 3 OnTarget trial in breast cancer patients
